| Year |
Citation |
Score |
| 2022 |
Chaudhary NS, Armstrong ND, Hidalgo BA, Gutiérrez OM, Hellwege JN, Limdi NA, Reynolds RJ, Judd SE, Nadkarni GN, Lange L, Winkler CA, Kopp JB, Arnett DK, Tiwari HK, Irvin MR. gene interacts with in the development of end-stage kidney disease: A genome-wide association study. Frontiers in Medicine. 9: 971297. PMID 36250097 DOI: 10.3389/fmed.2022.971297 |
0.419 |
|
| 2022 |
Armstrong ND, Srinivasasainagendra V, Chekka LMS, Nguyen NHK, Nahid NA, Jones AC, Tanner RM, Hidalgo BA, Limdi NA, Claas SA, Gong Y, McDonough CW, Cooper-DeHoff RM, Johnson JA, Tiwari HK, et al. Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. Genes. 13. PMID 35886043 DOI: 10.3390/genes13071260 |
0.428 |
|
| 2021 |
Armstrong ND, Srinivasasainagendra V, Patki A, Tanner RM, Hidalgo BA, Tiwari HK, Limdi NA, Lange EM, Lange LA, Arnett DK, Irvin MR. Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies. Frontiers in Genetics. 12: 781451. PMID 34992631 DOI: 10.3389/fgene.2021.781451 |
0.451 |
|
| 2020 |
Lee CR, Thomas CD, Beitelshees AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, et al. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clinical Pharmacology and Therapeutics. PMID 32897581 DOI: 10.1002/Cpt.2039 |
0.345 |
|
| 2019 |
Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, et al. Genetic factors influencing warfarin dose in Black-African patients: a systematic review and meta-analysis. Clinical Pharmacology and Therapeutics. PMID 31869433 DOI: 10.1002/Cpt.1755 |
0.357 |
|
| 2019 |
Chaudhary NS, Bridges SL, Saag KG, Rahn EJ, Curtis JR, Gaffo A, Limdi NA, Levitan EB, Singh JA, Colantonio LD, Howard G, Cushman M, Flaherty ML, Judd S, Irvin MR, et al. Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA11913. PMID 31786980 DOI: 10.1161/Hypertensionaha.119.13580 |
0.352 |
|
| 2019 |
Cai A, Dillon C, Hillegass WB, Beasley M, Brott BC, Bittner VA, Perry GJ, Halade GV, Prabhu SD, Limdi NA. Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. 8: e012874. PMID 31701784 DOI: 10.1161/Jaha.119.012874 |
0.341 |
|
| 2019 |
Irvin MR, Sitlani CM, Floyd JS, Psaty BM, Bis JC, Wiggins KL, Whitsel EA, Sturmer T, Stewart J, Raffield L, Sun F, Liu CT, Xu H, Cupples AL, Tanner RM, ... ... Limdi N, et al. Genome wide association study of apparent treatment resistant hypertension in the CHARGE consortium: The CHARGE Pharmacogenetics Working Group. American Journal of Hypertension. PMID 31545351 DOI: 10.1093/Ajh/Hpz150 |
0.419 |
|
| 2019 |
Do AN, Zhao W, Baldridge AS, Raffield LM, Wiggins KL, Shah SJ, Aslibekyan S, Tiwari HK, Limdi N, Zhi D, Sitlani CM, Taylor KD, Psaty BM, Sotoodehnia N, Brody JA, et al. Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans. Molecular Genetics & Genomic Medicine. e788. PMID 31407531 DOI: 10.1002/Mgg3.788 |
0.467 |
|
| 2019 |
Davis BH, Dillon C, Cai A, Williams Iii LA, Pamboukian SV, Limdi NA. Between a rock and a hard place: a high-risk patient with resistance to multiple P2Y antagonists. Pharmacogenomics. 20: 475-481. PMID 31124414 DOI: 10.2217/Pgs-2018-0201 |
0.323 |
|
| 2019 |
Davis BH, Boehme AK, Pamboukian SV, Allon M, George JF, Dillon C, Kirklin JK, Tallaj J, Levitan EB, Griffin R, McGwin G, Beasley TM, Limdi NA. Improvement in Kidney Function After Ventricular Assist Device Implantation and Its Influence on Thromboembolism, Hemorrhage, and Mortality. Asaio Journal (American Society For Artificial Internal Organs : 1992). PMID 30883405 DOI: 10.1097/Mat.0000000000000989 |
0.531 |
|
| 2019 |
Zhao X, Geng X, Srinivasasainagendra V, Chaudhary N, Judd S, Wadley V, Gutiérrez OM, Wang H, Lange EM, Lange LA, Woo D, Unverzagt FW, Safford M, Cushman M, Limdi N, et al. A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study. Bmc Medical Genomics. 12: 26. PMID 30704471 DOI: 10.1186/S12920-018-0462-7 |
0.456 |
|
| 2019 |
Chaudhary NS, Gaffo AL, Cushman M, Colantonio LD, Levitan EB, Judd SE, Singh J, Limdi NA, Bridges SL, Howard G, Reynolds RJ, Irvin MR. Abstract 188: Association Between Uric Acid and Stroke in the REgards Case-cohort Study Stroke. 50. DOI: 10.1161/Str.50.Suppl_1.188 |
0.337 |
|
| 2018 |
Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Botton MR, Bourgeois S, Deloukas P, Caldwell MD, ... ... Limdi NA, et al. The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals. Clinical Pharmacology and Therapeutics. PMID 30506689 DOI: 10.1002/Cpt.1323 |
0.368 |
|
| 2018 |
Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics. PMID 30345882 DOI: 10.2217/Pgs-2018-0146 |
0.389 |
|
| 2018 |
Irvin MR, Sitlani CM, Noordam R, Avery CL, Bis JC, Floyd JS, Li J, Limdi NA, Srinivasasainagendra V, Stewart J, de Mutsert R, Mook-Kanamori DO, Lipovich L, Kleinbrink EL, Smith A, et al. Genome-wide meta-analysis of SNP-by9-ACEI/ARB and SNP-by-thiazide diuretic and effect on serum potassium in cohorts of European and African ancestry. The Pharmacogenomics Journal. PMID 29855607 DOI: 10.1038/S41397-018-0021-9 |
0.459 |
|
| 2018 |
Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. Pharmacotherapy. PMID 29393514 DOI: 10.1002/Phar.2089 |
0.336 |
|
| 2017 |
Do AN, Zhao W, Srinivasasainagendra V, Aslibekyan S, Tiwari HK, Limdi N, Shah SJ, Zhi D, Broeckel U, Gu CC, Rao DC, Schwander K, Smith JA, Kardia SLR, Arnett DK, et al. Whole exome analyses to examine the impact of rare variants on left ventricular traits in African American participants from the HyperGEN and GENOA studies. Journal of Hypertension and Management. 3. PMID 29503979 DOI: 10.23937/2474-3690/1510025 |
0.426 |
|
| 2017 |
Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA. Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. PMID 28949423 DOI: 10.1002/Phar.2032 |
0.302 |
|
| 2017 |
Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenetics and Genomics. PMID 28806200 DOI: 10.1097/Fpc.0000000000000298 |
0.331 |
|
| 2017 |
Albright KC, Howard VJ, Howard G, Muntner P, Bittner V, Safford MM, Boehme AK, Rhodes JD, Beasley TM, Judd SE, McClure LA, Limdi N, Blackburn J. Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study. Journal of the American Heart Association. 6. PMID 28768644 DOI: 10.1161/Jaha.117.005523 |
0.54 |
|
| 2017 |
Liu N, Irvin MR, Zhi D, Patki A, Beasley TM, Nickerson DA, Hill CE, Chen J, Kimmel SE, Limdi NA. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array. Pharmacogenomics. PMID 28686080 DOI: 10.2217/Pgs-2017-0046 |
0.351 |
|
| 2017 |
Boehme AK, Pamboukian SV, George JF, Beasley TM, Kirklin JK, Tallaj J, Dillon C, Levitan EB, Griffin R, McGwin G, Hillegass WB, Limdi NA. Anticoagulation Control in Patients With Ventricular Assist Devices. Asaio Journal (American Society For Artificial Internal Organs : 1992). PMID 28492415 DOI: 10.1097/Mat.0000000000000592 |
0.567 |
|
| 2017 |
Shendre A, Irvin MR, Wiener H, Zhi D, Limdi NA, Overton ET, Shrestha S. Local Ancestry and Clinical Cardiovascular Events Among African Americans From the Atherosclerosis Risk in Communities Study. Journal of the American Heart Association. 6. PMID 28396569 DOI: 10.1161/Jaha.116.004739 |
0.324 |
|
| 2017 |
Ko D, Thigpen JL, Otis JA, Forster K, Henault L, Quinn E, Tripodis Y, Berger PB, Limdi N, Hylek EM. Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. International Journal of Cardiology. 227: 808-812. PMID 28273786 DOI: 10.1016/J.Ijcard.2016.10.055 |
0.312 |
|
| 2017 |
Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, et al. Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology and Therapeutics. PMID 28198005 DOI: 10.1002/Cpt.668 |
0.344 |
|
| 2016 |
Dawood FZ, Judd S, Howard VJ, Limdi NA, Meschia JF, Cushman M, Howard G, Herrington DM, Soliman EZ. High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study). The American Journal of Cardiology. PMID 27712649 DOI: 10.1016/J.Amjcard.2016.08.069 |
0.345 |
|
| 2016 |
Bajaj NS, Kalra R, Patel N, Hashim T, Godara H, Ather S, Arora G, Pasala T, Whitfield TT, McGiffin DC, Ahmed MI, Lloyd SG, Limdi NA, Arora P. Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials. Plos One. 11: e0163608. PMID 27706224 DOI: 10.1371/Journal.Pone.0163608 |
0.319 |
|
| 2016 |
O'Neal WT, Judd SE, Limdi NA, McIntyre WF, Kleindorfer DO, Cushman M, Howard VJ, Howard G, Soliman EZ. Differential Impact of Risk Factors in Blacks and Whites in the Development of Atrial Fibrillation: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Journal of Racial and Ethnic Health Disparities. PMID 27531069 DOI: 10.1007/S40615-016-0275-3 |
0.343 |
|
| 2016 |
French B, Wang L, Gage BF, Horenstein RB, Limdi NA, Kimmel SE. A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenetics and Genomics. PMID 27383664 DOI: 10.1097/Fpc.0000000000000235 |
0.313 |
|
| 2016 |
Ather S, Shendre A, Beasley TM, Brown T, Hill CE, Prabhu SD, Limdi NA. Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. The American Journal of Cardiology. PMID 27241839 DOI: 10.1016/J.Amjcard.2016.04.047 |
0.375 |
|
| 2016 |
Shendre A, Brown TM, Liu N, Hill CE, Beasley TM, Nickerson DA, Limdi NA. Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. PMID 26877068 DOI: 10.1002/Phar.1717 |
0.387 |
|
| 2016 |
Albright KC, Boehme AK, Tanner RM, Blackburn J, Howard G, Howard VJ, Safford M, Beasley TM, Limdi N. Addressing Stroke Risk Factors in Black and White Americans: Findings from the National Health and Nutrition Examination Survey, 2009-2010. Ethnicity & Disease. 26: 9-16. PMID 26843791 DOI: 10.18865/Ed.26.1.9 |
0.548 |
|
| 2015 |
Limdi NA, Howard VJ, Higginbotham J, Parton J, Safford MM, Howard G. US Mortality: Influence of Race, Geography and Cardiovascular Risk Among Participants in the Population-Based REGARDS Cohort. Journal of Racial and Ethnic Health Disparities. PMID 27294752 DOI: 10.1007/S40615-015-0179-7 |
0.335 |
|
| 2015 |
Boehme AK, Pamboukian SV, George JF, Dillon C, Levitan EB, Griffin R, Beasley TM, McGwin G, Kirklin JK, Limdi NA. Predictors of Thromboembolic Events in Patients with Ventricular Assist Device. Asaio Journal (American Society For Artificial Internal Organs : 1992). 61: 640-7. PMID 26418204 DOI: 10.1097/Mat.0000000000000284 |
0.556 |
|
| 2015 |
Aronis KN, Thigpen JL, Tripodis Y, Dillon C, Forster K, Henault L, Quinn EK, Berger PB, Limdi NA, Hylek EM. Paroxysmal atrial fibrillation and the hazards of under-treatment. International Journal of Cardiology. 202: 214-220. PMID 26397414 DOI: 10.1016/J.Ijcard.2015.09.006 |
0.348 |
|
| 2015 |
Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, et al. Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 16: 1-11. PMID 26265036 DOI: 10.2217/Pgs.15.73 |
0.323 |
|
| 2015 |
Gutiérrez OM, Judd SE, Irvin MR, Zhi D, Limdi N, Palmer ND, Rich SS, Sale MM, Freedman BI. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 26152403 DOI: 10.1093/Ndt/Gfv229 |
0.303 |
|
| 2015 |
Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM. Race influences warfarin dose changes associated with genetic factors. Blood. 126: 539-45. PMID 26024874 DOI: 10.1182/Blood-2015-02-627042 |
0.541 |
|
| 2015 |
Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 65: 701-9. PMID 25468385 DOI: 10.1053/J.Ajkd.2014.11.004 |
0.348 |
|
| 2015 |
Ather S, Shendre AD, Prabhu S, Limdi N. Effect Of Left Ventricular Systolic Dysfunction On Warfarin Dose Journal of the American College of Cardiology. 65. DOI: 10.1016/S0735-1097(15)61060-9 |
0.306 |
|
| 2014 |
Do AN, Irvin MR, Lynch AI, Claas SA, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Tiwari HK, Limdi NA, Arnett DK. The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study. Frontiers in Pharmacology. 5: 210. PMID 25278896 DOI: 10.3389/Fphar.2014.00210 |
0.508 |
|
| 2014 |
Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, Limdi N, Hillenmeyer S, Percha B, Karczewski KJ, Langaee T, Patel SR, Bustamante CD, Altman RB, Perera MA. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 124: 2298-305. PMID 25079360 DOI: 10.1182/Blood-2014-04-568436 |
0.388 |
|
| 2014 |
Shendre A, Beasley TM, Brown TM, Hill CE, Arnett DK, Limdi NA. Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications. Pharmacotherapy. 34: 545-54. PMID 25032265 DOI: 10.1002/Phar.1401 |
0.498 |
|
| 2013 |
Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER, Fang MC, ... ... Limdi NA, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. The New England Journal of Medicine. 369: 2283-93. PMID 24251361 DOI: 10.1056/Nejmoa1310669 |
0.31 |
|
| 2013 |
Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 382: 790-6. PMID 23755828 DOI: 10.1016/S0140-6736(13)60681-9 |
0.373 |
|
| 2013 |
Limdi MA, Crowley MR, Beasley TM, Limdi NA, Allon M. Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 61: 354-7. PMID 23159233 DOI: 10.1053/J.Ajkd.2012.09.012 |
0.375 |
|
| 2012 |
Limdi NA. Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Frontiers in Pharmacology. 3: 183. PMID 23133417 DOI: 10.3389/Fphar.2012.00183 |
0.308 |
|
| 2012 |
Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and Haemostasis. 107: 232-40. PMID 22186998 DOI: 10.1160/Th11-06-0388 |
0.356 |
|
| 2011 |
Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics (Oxford, England). 27: 1384-9. PMID 21450715 DOI: 10.1093/Bioinformatics/Btr159 |
0.306 |
|
| 2010 |
Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, Allon M, Beasley TM. Warfarin dosing in patients with impaired kidney function. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 56: 823-31. PMID 20709439 DOI: 10.1053/J.Ajkd.2010.05.023 |
0.367 |
|
| 2010 |
Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clinical Pharmacology and Therapeutics. 87: 572-8. PMID 20375999 DOI: 10.1038/Clpt.2010.13 |
0.326 |
|
| 2010 |
Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 115: 3827-34. PMID 20203262 DOI: 10.1182/Blood-2009-12-255992 |
0.357 |
|
| 2010 |
Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. Journal of Clinical Epidemiology. 63: 960-9. PMID 19995676 DOI: 10.1016/J.Jclinepi.2009.09.006 |
0.341 |
|
| 2009 |
DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA. Hyperammonemia following intravenous valproate loading. Epilepsy Research. 85: 65-71. PMID 19299111 DOI: 10.1016/J.Eplepsyres.2009.02.012 |
0.305 |
|
| 2009 |
Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy Blood Cells, Molecules, and Diseases. 43: 119-128. PMID 19297219 DOI: 10.1016/J.Bcmd.2009.01.019 |
0.413 |
|
| 2009 |
Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. Journal of the American Society of Nephrology : Jasn. 20: 912-21. PMID 19225037 DOI: 10.1681/Asn.2008070802 |
0.492 |
|
| 2009 |
Goldstein JA, Blaisdell JA, Limdi NA. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy Blood Cells, Molecules, and Diseases. 42: 155-158. PMID 19083245 DOI: 10.1016/J.Bcmd.2008.10.011 |
0.327 |
|
| 2008 |
Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 9: 1445-58. PMID 18855533 DOI: 10.2217/14622416.9.10.1445 |
0.501 |
|
| 2008 |
Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 9: 1331-46. PMID 18781859 DOI: 10.2217/14622416.9.9.1331 |
0.361 |
|
| 2008 |
Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 9: 511-26. PMID 18466099 DOI: 10.2217/14622416.9.5.511 |
0.543 |
|
| 2008 |
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clinical Pharmacology and Therapeutics. 83: 312-21. PMID 17653141 DOI: 10.1038/Sj.Clpt.6100290 |
0.505 |
|
| 2007 |
Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia. 48: 478-83. PMID 17319914 DOI: 10.1111/J.1528-1167.2007.00989.X |
0.307 |
|
| 2007 |
Limdi NA, Goldstein JA, Blaisdell JA, Beasley TM, Rivers CA, Acton RT. Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans Personalized Medicine. 4: 157-169. DOI: 10.2217/17410541.4.2.157 |
0.387 |
|
| 2007 |
Limdi NA, Acton RT, Beasely TM, Adler B. The Influence of CYP2C9 and VKORC1 1173C/T Genotype on Reversal of Anticoagulation (INR) Following Phytonadione Administration. Blood. 110: 3135-3135. DOI: 10.1182/Blood.V110.11.3135.3135 |
0.371 |
|
| 2006 |
Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy Blood Cells, Molecules, and Diseases. 37: 100-106. PMID 16889993 DOI: 10.1016/J.Bcmd.2006.06.003 |
0.349 |
|
| 2004 |
Limdi NA, Lemons NV, Gomez CR. Superiority of fixed-dose warfarin for chronic anticoagulation. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association. 13: 118-21. PMID 17903962 DOI: 10.1016/J.Jstrokecerebrovasdis.2004.04.003 |
0.352 |
|
| Show low-probability matches. |